Mutations in some genes are known to increase the risk of developing certain types of cancer. A child has a 50% probability of inheriting mutated gene(s) from his/her parent.
Our genetic test package for hereditary cancer risks include the analysis of 49 genes for 17 types of cancer.
You may want to consider taking up a genetic test for hereditary cancer if one or more of the following exist in your extended family:
1. A blood kin* of yours has had multiple cancer types.
2. A blood kin of yours has had a rare cancer type (e.g. breast cancer in a male relative).
3. A blood kin of yours has had a positive genetic test for hereditary cancer.
4. Two or more of your blood kin have had cancer at an early age (< 55 year-old).
* blood-kin refers to relatives with blood-bond (e.g. 1st degree: parents and siblings; 2nd degree: grandparents, aunts, uncles, nephews, nieces or half-siblings)
Targeted Drug Chemotherapy
Targeted-drug chemotherapy (TDC) works by “differentiating” the cancer cells from the normal healthy cells to increase effectiveness and minimize side effects.
In principle, a drug for TDC targets a “specific component” that is predominantly expressed in the cancer cells compared to the normal healthy cells.
Our comprehensive genetic test package allows us to screen for these “specific components” (based on 206 genes) in the cancer cells to determine if such “specific components” could be sensitive or resistant to the panel of TDC drugs (up to 95 of them). This could potentially help in providing the patient with a customized TDC for better outcomes in treatment.